{"url_path":"/sec/klrs/8-k/2026-06-04/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-04","source_url":"https://www.sec.gov/Archives/edgar/data/1754068/0001193125-26-257388-index.html","accession_number":"0001193125-26-257388","cik":"0001754068","ticker":"KLRS","issuer_name":"Kalaris Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1754068/0001193125-26-257388-index.html","primary_entity_key":"0001754068","primary_entity_name":"Kalaris Therapeutics, Inc."},"word_count":365,"has_tables":true,"body_markdown":"Item 5.07\n\nSubmission of Matters to a Vote of Security Holders.\n\nKalaris Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders on June 3, 2026. The following is a summary of the matters voted on at that meeting.\n\n \n\n \n1.\n\nThe stockholders of the Company elected Napoleone Ferrara, M.D., David Hallal and Leone Patterson as Class III directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her respective successor has been duly elected and qualified. The results of the stockholders’ vote with respect to such matter were as follows:\n\n \n\n \n  \nFor\n \n  \nWithheld\n \n  \nBroker Non-\nVotes\n \n\nNapoleone Ferrara, M.D.\n\n  \n \n15,619,403\n \n  \n \n733,571\n \n  \n \n3,420,470\n \n\nDavid Hallal\n\n  \n \n15,623,189\n \n  \n \n729,785\n \n  \n \n3,420,470\n \n\nLeone Patterson\n\n  \n \n15,858,093\n \n  \n \n494,881\n \n  \n \n3,420,470\n \n\n \n\n \n2.\n\nThe stockholders of the Company approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers. The results of the stockholders’ vote, on a non-binding advisory basis, with respect to such matter were as follows:\n\n \n\nFor\n\n \n\nAgainst\n\n \n\nAbstain\n\n \n\nBroker Non-\nVotes\n\n15,852,844\n \n495,763\n \n4,366\n \n3,420,470\n\n \n\n \n3.\n\nThe stockholders of the Company recommended, on a non-binding advisory basis, that future advisory votes on the compensation of the Company’s named executive officers be held every year. The results of the stockholders’ vote, on a non-binding advisory basis, with respect to such matter were as follows:\n\n \n\nOne Year\n\n \n\nTwo\n\nYears\n\n \n\nThree\n\nYears\n\n \n\nAbstain\n\n \n\nBroker Non-\n\nVotes\n\n16,336,117\n \n875\n \n11,154\n \n4,827\n \n3,420,470\n\nAfter taking into consideration the foregoing voting results, the Board of Directors of the Company intends to hold future advisory votes on the compensation of the Company’s named executive officers every year.\n\n \n\n \n4.\n\nThe stockholders of the Company ratified the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the stockholders’ vote with respect to such matter were as follows:\n\n \n\nFor\n\n \n\nAgainst\n\n \n\nAbstain\n\n19,771,260\n \n1,583\n \n601\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \nKALARIS THERAPEUTICS, INC.\n\nDate: June 4, 2026\n \n\n \nBy:\n \n\n/s/ Andrew Oxtoby\n\n \n\n \nName:\n \nAndrew Oxtoby\n\n \n\n \nTitle:\n \nChief Executive Officer"}